Imatinib mesylate (STI571 or Gleevec) is a specific inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukaemia. Other targets ATP-binding site of tyrosine kinases are for PDGF, PDGF-receptor, c-Kit, and SCF.